Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial

Benzinga_recent_news01-08

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Tuesday shared efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial of Ziihera (zanidatamab-hrii) for HER2-positive (HER2+) locally advanced or ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601383883?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/07/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-01-08 02:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601383883","market":"hk","top_or_hot":-1,"title":"Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial","media":"Benzinga_recent_news","content":"<div>\n<p>Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Tuesday shared efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial of Ziihera (zanidatamab-hrii) for HER2-positive (HER2+) locally advanced or ...</p>\n\n<a href=\"https://www.benzinga.com/news/financing/26/01/49763409/jazz-pharmaceuticals-drug-extends-survival-past-two-years-in-advanced-stomach-cancer-trial\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-08 02:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/financing/26/01/49763409/jazz-pharmaceuticals-drug-extends-survival-past-two-years-in-advanced-stomach-cancer-trial><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Tuesday shared efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial of Ziihera (zanidatamab-hrii) for HER2-positive (HER2+) locally advanced or ...</p>\n\n<a href=\"https://www.benzinga.com/news/financing/26/01/49763409/jazz-pharmaceuticals-drug-extends-survival-past-two-years-in-advanced-stomach-cancer-trial\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AEIS","symbol_name":"先进能源工业公司","start_time":0,"source_url":"https://www.benzinga.com/news/financing/26/01/49763409/jazz-pharmaceuticals-drug-extends-survival-past-two-years-in-advanced-stomach-cancer-trial","article_id":"2601383883","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/07/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/financing/26/01/49763409/jazz-pharmaceuticals-drug-extends-survival-past-two-years-in-advanced-stomach-cancer-trial","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2601383883","pubTimestamp":1767809520,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Jazz Pharmaceuticals reported Phase 3 trial results showing Ziihera helped patients with advanced HER2-positive stomach cancer live longer, with some treatments pushing survival beyond two years.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"AEIS":"先进能源工业公司","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","BK4157":"电子设备和仪器","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","OS":"OneStream, Inc.","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","JAZZ":"爵士制药","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","BK4195":"互助储蓄与抵押信贷金融服务","BK4007":"制药","BK4211":"区域性银行","PFS":"Provident Financial Services Inc","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BK4097":"系统软件","ZYME":"ZYMEWORKS INC (US)","BK4532":"文艺复兴科技持仓","ONC":"百济神州","BK4526":"热门中概股","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","BK4585":"ETF&股票定投概念","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4139":"生物科技","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"Jazz Pharmaceuticals的药物在晚期胃癌试验中延长了两年的生存期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OS":1,"PFS":1,"ONC":1,"JAZZ":1,"AEIS":1.5,"ZYME":1},"content_text":"Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Tuesday shared efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial of Ziihera (zanidatamab-hrii) for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA).\nGEA includes cancers of the stomach, gastroesophageal junction, and esophagus.\nIn November 2025, Jazz Pharmaceuticals and its partners Zymeworks Inc. (NASDAQ:ZYME) and BeOne Medicines Inc. (NASDAQ:ONC) announced topline results from the Phase 3 HERIZON-GEA-01 trial.\nThe trial evaluated Ziihera in combination with chemotherapy, with or without BeOne’s Tevimbra (tislelizumab), as first-line treatment.\nThe data will be presented at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO-GI).\nBoth investigational arms, Ziihera plus tislelizumab and chemotherapy, and Ziihera plus chemotherapy, led to a statistically significant and clinically meaningful prolongation of progression-free survival (PFS).\nThe doublet therapy (Ziihera+chemo) showed a PFS improvement of 35% and the triplet therapy (Ziihera+tislelizumab+chemo) showed approximately a 37% reduction in the risk of disease progression or death.\nThis resulted in a median PFS of more than one year, representing a greater than four-month improvement compared to the control arm.\nThe triplet therapy demonstrated a meaningful overall survival (OS) benefit with a median OS of more than two years (26.4 months).\nThe company on Tuesday added that it is the longest reported in a Phase 3 trial in GEA, representing a greater than seven-month improvement in median OS and a 28% reduction in the risk of death versus trastuzumab plus chemotherapy.\nAt this first interim analysis, the doublet therapy showed a median OS of more than two years (24.4 months), with a strong trend toward statistical significance, favoring Ziihera plus chemotherapy versus trastuzumab plus chemotherapy.\nThough not statistically significant, the doublet therapy showed a preliminary 20% death risk reduction, with a p-value of 0.0564.\nAn additional planned OS interim analysis for Ziihera plus chemotherapy is currently expected in mid-2026.\n“Reaching more than two years of median overall survival in a global Phase 3 trial for HER2+ metastatic GEA is truly unprecedented,” said Elena Elimova, Princess Margaret Cancer Centre.\nJAZZ Price Action: Jazz Pharmaceuticals shares were up 2.07% at $170.44 at the time of publication on Wednesday, according to Benzinga Pro data.\nPhoto by Aunt Spray via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601383883","isCrawlerRequest":true}